References

Поставить закладку

Briko N.I., ed. [Epidemiology, Clinics, and Prevention of Pneumococcal Infection. A Study Guide for Physicians]. Nizhniy Novgorod: Remedium Privolzh'e; 2017 (in Russian).
Tatochenko V.K., Ozeretskovskiy N.A. [Preventive Immunization. 2018. A Manual]. The 13th Revised Edition. Moscow: Borges; 2018 (in Russian).
Pollard A.J., Perrett K.P., Beverley P.C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 2009; 9 (3): 213–220. DOI: 10.1038/nri2494.
Caplan A., Fett N., Rosenbach M. et al. Prevention and management of glucocorticoid-induced side effects: A comprehensive review. Infectious complications and vaccination recommendations. J. Am. Acad. Dermatol. 2017; 76 (2): 191–198. DOI: 10.1016/j.jaad.2016.02.1240.
Siegrist C.A., Aspinall R. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol. 2009; 9 (3): 185–194. DOI: 10.1038/nri2508.
Huijts S.M., van Werkhoven C.H., Bolkenbaas M. et al. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly. Vaccine. 2017; 35 (34): 4444–4449. DOI: 10.1016/j.vaccine.2017.01.071.
Shea K.M., Edelsberg J., Weycker D. et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect. Dis. 2014; 1 (1): ofu024. DOI: 10.1093/ ofid/ofu024.
Luján M., Burgos J., Gallego M. et al. Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: implications for vaccine strategies. Clin. Infect. Dis. 2013; 57 (12): 1722–1730. DOI: 10.1093/cid/cit640.
Kostinov M.P., Chuchalin A.G., ed. [A Handbook on Clinical Immunology in Respiratory Medicine]. The 2nd Revised Edition. Moscow: MDV; 2018 (in Russian).
Koch D.H., Moon K.T., Kim J.Y. et al. The risk of hospitalization for infectious pneumonia in mineral dust exposed industries. Occup. Environ. Med. 2011; 68 (2): 116–119. DOI: 10.1136/oem.2009.051334.
Coggon D., Harris E.C., Cox V., Palmer K.T. Pneumococcal vaccination for welders. Thorax. 2015; 70 (2): 198–199. DOI: 10.1136/thoraxjnl-2014-206129.
Lobzin Y.V., Sidorenko S.V., Kharit S.M. et al. [Streptococcus pneumoniae serotypes causing major pneumococcal infections]. Zhurnal infektologii. 2013; 5 (4): 36–42 (in Russian).
Beloshitskiy G.V., Korolyova I.S., Mironov K.O. [Phenotypic and genotypic characteristics of pneumococci isolated from patients with pneumococcal meningitis]. Klinitcheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2011; 13 (3): 261–266 (in Russian).
Siegrist C.A. Vaccine immunology. In: Plotkin S.A., Orenstein W.A., Offit P.A., eds. Vaccines. The 6th Edition. Philadelphia: Elsevier-Saunders; 2013.
Bonten M.J.M., Huijts S.M., Bolkenbaas M. et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N. Eng. J. Med. 2015; 372: 1114–1125. DOI: 10.1056/NEJMoa1408544.
Falkenhorst G., Remschmidt C., Harder T. et al. [Background paper to the updated pneumococcal vaccination recommendation for older adults in Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016; 59 (12): 1623–1657. DOI: 10.1007/ s00103-0162466-9 (in German).
Gonzalez-Romo F., Picazo J.J. Rojas A.G. et al. [Consensus document on pneumococcal vaccination in adults at risk by age and underlying clinical conditions. 2017 Update]. Rev. Esp. Quimioter. 2017; 30 (2): 142–168. Available at: http:// www.seq.es/seq/0214-3429/30/2/gonzalez15feb2017.pdf (in Spanish).
Australian Government Department of Health. Australian Immunisation Handbook. The National Immunisation Program. Available at: http://www.health.gov.au/internet/ immunise/publishing.nsf/Content/national-immunisation-program-schedule
Center for Disease Control and Prevention. Pneumococcal Diseases. Pneumococcal Vaccination. Available at: https:// www.cdc.gov/pneumococcal/vaccination.html
Tin Tin Htar M., Stuurman A.L., Ferreira G. et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLoS One. 2017; 12 (5): e0177985. DOI: 10. 1371/journal.pone.0177985.
Center for Disease Control and Prevention. Vaccine Recommendations and Guidelines of the ACIP. Available at: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/ immunocompetence.html
van Cuyck H., Pichon B., Leroy P. et al. Multiple-locus variable-number tandem-repeat analysis of Streptococcus pneumoniae and comparison with multiple loci sequence typing. BMC Microbiology. 2012; 12: 241. DOI: 10.1186/1471-218012-241.
Martynova A.V., Balabanova L.A., Chulakova O.A., Sheparev A.A. [Molecular epidemiological monitoring of Streptococcus pneumoniae strains isolated from elderly patients with community-acquired pneumonia]. STM. 2014; 6 (3): 91–96. Available at: https://cyberleninka.ru/article/v/ molekulyarno-epidemiologicheskiy-monitoring-shtammovstreptococcus-pneumoniae-vydelennyh-u-patsientov-pozhilogo-vozrasta-s (in Russian).
Demko I.V., Korchagin E.E., Gordeeva N.V. et al. [An experience of vaccination against pneumococcal infection of adults at Krasnoyarsk krai]. Pul'monologiya. 2017; 27 (1): 21–28. DOI: 10.18093/0869-0189-2017-27-1-21-28 (in Russian).
Zakharova I.A. [Possibilities to prevent acute exacerbations of chronic bronchitis in young patients]. Sovremennye problemy nauki i obrazovaniya. 2016; 5 (in Russian).
Ignatova G.L., Antonov V.N. [Epidemiological characteristics of chronic respiratory diseases in patients vaccinated against pneumococcal infection]. Pul'monologiya. 2017; 27 (3): 376–383. DOI: 10.18093/0869-0189-2017-27-3-376383 (in Russian).
Ignatova G.L., Antonov V.N. [Efficacy of preventive vaccination against pneumococcal infection in patients with chronic obstructive pulmonary disease and comorbidity]. Epidemiologiya i vaktsinoprofilaktika. 2017; 16 (5): 22–27. DOI: 10.31631/2073-3046-2017-16-5-22-27 (in Russian).
Clinical Guidelines. Chronic Heart Failure. A Society of Specialists on Heart Failure. Russian Society of Cardiologists. Available at: www.ossn.ru/upload/medialibrary/003/ РекомендацииОССН_МЗ_30012017.pdf (in Russian).
Protasov A.D., Zhestkov A.V., Kostinov M.P. et al. [An analysis of long-term efficacy and adaptive immunity development under the use of different vaccines and vaccination schemes against pneumococcal infection in patients with chronic obstructive pulmonary disease]. Terapevticheskiy arkhiv. 2017; 89 (12-2): 165–174 (in Russian).
Golodnova S.O., Feldblyum I.V., Semerikov V.V. et al. [The prevalence of Streptococcus pneumoniae carriage and evaluation of preventive vaccination in healthcare workers]. Epidemiologiya i vaktsinoprofilaktika. 2014; 1 (74): 50–54 (in Russian).
Fel'dblyum I.V., Nikolenko V.V., Vorob'eva N.N. et al. [Reactogenicity, safety, immunogenicity and efficacy of polysaccharide pneumococcal vaccine in HIV-infected patients]. Zhurnal mikrobiologii, epidemiologii, immunobiologii. 2013; (3): 52–60 (in Russian).
Nikolenko V.V., Feldblyum I.V., Golodnova S.O., Vorobiova N.N. [Healthcare workers as a high-risk group for pneumococcal infection]. Meditsinskiy al'manakh. 2014; 4 (34): 30–34 (in Russian).
Chuchalin A.G., Onishchenko G.G., Kolosov V.P. et al. [Anti-epidemic measured for prevention of pneumococcal infections in f looded areas of the Amur region]. Pul'monologiya. 2015; 25 (3): 303–311. DOI: 10.18093/0869-01892015-25-3-303-311 (in Russian).
Rubin L.G., Levin M.J., Ljungman P. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin. Infect. Dis. 2014; 58 (3): 309–318. DOI: 10.1093/cid/cit816.
U.S. National Library of Medicine. Pneumococcal Vaccine in Untreated CLL (Chronic Lymphocytic Leukemia) Patients. ClinicalTrials.gov NCT01892618. Available at: https://clinicaltrials.gov/ct2/show/NCT01892618?term=NCT0 1892618&rank=1
U.S. National Library of Medicine. VACcination In Methotrexate Treated Rheumatoid Arthritis Patients (VACIMRA). ClinicalTrials.gov NCT01942174. Available at: https://clinicaltrials.gov/ct2/show/NCT01942174?term= NCT01942174&rank=1
McLaughlin J.M., Jiang Q., Isturiz R.E. et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: A test-negative design. Clin. Infect. Dis. 2018; 67 (10): 1498–1506. DOI: 10.1093/cid/ciy312.
Greenberg R.N., Gurtman A., Frenck R.W. et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60–64 years of age. Vaccine. 2014; 32 (20): 2364–2374. DOI: 10.1016/j.vaccine.2014.02.002.
Paradiso P.R. Pneumococcal conjugate vaccine for adults: a new paradigm. Clin. Infect. Dis. 2012; 55 (2): 259–264. DOI: 10.1093/cid/cis359.
U.S. National Library of Medicine. Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029). ClinicalTrials.gov NCT02225587. August 26, 2014. Available at: https://clinicaltrials.gov/ct2/results?cond=&term=NCT02225587&cntry =&state=&city=&dist=Received March 17, 2019

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница